canadianguy340 wrote:Hes not gona suggest I go on them yet and only 30% chance they would stop any progression.
That's not entirely correct. More precisely, they reduce disability progression by a relative difference of about 30% compared to placebo. For example, take these
data plots for Avonex. The absolute difference for reduction of disability progression is just 13%. However, the relative difference is 37%, i.e., (34.9-21.9)/34.9*100. People still experienced disability progression, it was just slightly slower than it might have been without treatment.
Relative diffference is a blatant way the pharma companies use to make their drugs look better than the really are. Take for example a study that has 100 patients in a treatment group and 100 in a placebo group. If some drug is being tested and there was one fatality in the treatment group but 2 in the placebo group, then they are allowed to report that their drug reduces risk of fatality by 50%. However, such a drug is likely not even worth the bottle it's packaged in but now it can be marketed as reducing fatalities by an apparent 50%.
NHE